| Literature DB >> 24392930 |
Andrea Chiricozzi1, Rossella Pitocco, Rosita Saraceno, Steven Paul Nistico, Alessandro Giunta, Sergio Chimenti.
Abstract
INTRODUCTION: Psoriasis is a common immune-mediated disorder that in 70% of cases appears in mild or mild-to-moderate form. Psoriasis is usually treated with topical medications and/or phototherapy with variable efficacy in controlling the disease. AREAS COVERED: For the past three decades, research has been focused on systemic agents for the treatment of moderate-to-severe psoriasis, particularly with the introduction of biologic agents or 'small molecules'. In parallel, novel advances in topical antipsoriatic agents have been made, experiencing a 'new era', with the development of new formulations and the identification of new therapeutic targets. These agents, having a different spectrum of action from traditional agents, are actually being tested in pre-marketing clinical trials and they may potentially represent promising treatment options that could enlarge the therapeutic armamentarium for the treatment of psoriasis. EXPERT OPINION: Future antipsoriatic topical agents show new modality of action in blocking the pathogenic process leading to psoriatic plaque formation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24392930 DOI: 10.1517/14656566.2014.875159
Source DB: PubMed Journal: Expert Opin Pharmacother ISSN: 1465-6566 Impact factor: 3.889